Skip to Content
  • PARP Inhibitors Do It Again

    When we last looked in on the long-running saga of PARP inhibitors around here, Tesaro had posted excellent clinical results for their compound and re-invigorat… Read More
  • The Soon-Shiong Hype Machine

    I have long been suspicious of people who use the word “moonshot” in the context of biomedical research. It’s lazy shorthand for “WeR… Read More
  • Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old gen… Read More
  • Not Quite What Friends Are For

    Folks who do industrial drug research know that they’re around proprietary information, and they generally know to keep quiet about it. That can be a bit… Read More
  • Thoughts on Corruption

    I’ve had many questions about what I think of the PhARMA meeting with the new administration, but I haven’t written about it yet. That’s large… Read More
  • Eli Lilly Is a Biologics Company

    The news from Eli Lilly is not good – they’re laying off 485 people, according to filings with the state, and it appears to be completely a result o… Read More
  • The Hollywood Analogy

    Yesterday’s drug-research-is-hard screed brought a lot of responses, and I wanted to address some particular points that came up. On Twitter, Alex Tabarro… Read More
  • Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to wor… Read More
Page 1 of 10012345...102030...Last »